38947-57-8 Usage
Description
2,6-Diphenylisonicotinic acid, also known as 97, is a white to cream crystalline powder that can be synthesized by reacting ethyl 2,6-diphenylisonicotinate in ethanol with a KOH solution. It is a chemical compound with potential applications in various industries due to its unique properties.
Uses
Used in Pharmaceutical Industry:
2,6-Diphenylisonicotinic acid is used as a reactant for the synthesis of 7-substituted spiro[chroman-2,4′-piperidin]-4-one derivatives. These derivatives have potential applications in the development of new pharmaceutical compounds, particularly in the treatment of various medical conditions.
Used in Chemical Synthesis:
2,6-Diphenylisonicotinic acid is also used as a reactant in the synthesis of ethyl 2,6-diphenylisonicotinate, which is a tridentate ligand. Tridentate ligands are important in coordination chemistry and can be used to form complexes with metal ions, leading to the development of new materials and catalysts.
Check Digit Verification of cas no
The CAS Registry Mumber 38947-57-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,9,4 and 7 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 38947-57:
(7*3)+(6*8)+(5*9)+(4*4)+(3*7)+(2*5)+(1*7)=168
168 % 10 = 8
So 38947-57-8 is a valid CAS Registry Number.
InChI:InChI=1/C18H13NO2/c20-18(21)15-11-16(13-7-3-1-4-8-13)19-17(12-15)14-9-5-2-6-10-14/h1-12H,(H,20,21)
38947-57-8Relevant articles and documents
2,6-diphenylpyridine-4-carboxylic acid
Crispini, Alessandra,Neve, Francesco
, p. o34-o35 (2002)
The crystal structure of 2,6-diphenylpyridine-4-carboxylic acid, C18H13NO2 was studied. Dihedral angles between the plane of pyridine and those of the phenyl substituents were found to be 8.7 and 9.8 (1)°. The shortest int
Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists
Giardina,Artico,Cavagnera,Cerri,Consolandi,Gagliardi,Graziani,Grugni,Hay,Luttmann,Mena,Raveglia,Rigolio,Sarau,Schmidt,Zanoni,Farina
, p. 364 - 374 (2007/10/03)
Results from a medicinal chemistry approach aimed at replacing the quinoline ring system in the potent and selective human neurokinin-3 (hNK-3) receptor antagonists 1-4 of general formula I are discussed. The data give further insight upon the potential NK-3 pharmacophore. In particular, it is highlighted that both the benzene-condensed ring and the quinoline nitrogen are crucial determinants for optimal binding affinity to the hNK-3 receptor. Some novel compounds maintained part of the binding affinity to the receptor (5, 6, 10 and 13) and compound 5, featuring the naphthalene ring system, appears to be suitable for further modifications: it offers the option to introduce electron-withdrawing groups at position 2 and 4, conferring on the ring an overall electron-deficiency similar to that of the quinoline.
